Evidence map›Paper›PMID 23664839›Full record

ReviewExperimental cell research2013

Developmental windows of breast cancer risk provide opportunities for targeted chemoprevention.

Holly A Martinson, Traci R Lyons, Erin D Giles, Virginia F Borges, Pepper Schedin

Open access · hybridAbstract readReview
In one paragraph

Review in Experimental cell research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 67 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Macphatics and PoEMs in Postpartum Mammary Development and Tumor Progression.Journal of mammary gland biology and neoplasia · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Holly A MartinsonDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, MS8117, RC1S, 8401K, 12801 East 17th Avenue, Aurora, CO 80045, USA; Program in Cancer Biology, University of Colorado Anschutz Medical Campus, MS8104, RC1S, 5117, 12801 East 17th Avenue, Aurora, CO 80045, USA.
Traci R LyonsDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, MS8117, RC1S, 8401K, 12801 East 17th Avenue, Aurora, CO 80045, USA.
Erin D GilesDivision of Endocrinology, Metabolism and Diabetes, University of Colorado Anschutz Medical Campus School of Medicine, RC1S, Room 7103, 12801 East 17th Avenue, Mail Stop 8106, Aurora, CO 80045, USA; Anschutz Health and Wellness Center, 12348 East Montview Boulevard, Campus Box C263, Aurora, CO 80045, USA.
Virginia F BorgesDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, MS8117, RC1S, 8401K, 12801 East 17th Avenue, Aurora, CO 80045, USA; University of Colorado Cancer Center, Building 500, Suite 6004C, 13001 East 17th Place, Aurora, CO 80045, USA; Young Women's Breast Cancer Translational Program, University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, 1665 Aurora Court, Aurora, CO 80045, USA.
Pepper SchedinDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, MS8117, RC1S, 8401K, 12801 East 17th Avenue, Aurora, CO 80045, USA; Program in Cancer Biology, University of Colorado Anschutz Medical Campus, MS8104, RC1S, 5117, 12801 East 17th Avenue, Aurora, CO 80045, USA; University of Colorado Cancer Center, Building 500, Suite 6004C, 13001 East 17th Place, Aurora, CO 80045, USA; Young Women's Breast Cancer Translational Program, University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, 1665 Aurora Court, Aurora, CO 80045, USA. Electronic address: Pepper.Schedin@ucdenver.edu.
University of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · US

Funding

PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Wendy M Kohrt · 1995 to 2026
$32.6M
Endocrine Status of MG Stroma Alters Breast CA InvasionR01CA085944 · NCI · UNIVERSITY OF COLORADO DENVER · PI SCHEDIN, PEPPER J · 2001 to 2004
$1.1M
NCI NIH HHS R01 CA085944NIDDK NIH HHS DK048520NIDDK NIH HHS P30 DK048520
6 · The paper itself

Abstract

The magnitude of the breast cancer problem implores researchers to aggressively investigate prevention strategies. However, several barriers currently reduce the feasibility of breast cancer prevention. These barriers include the inability to accurately predict future breast cancer diagnosis at the individual level, the need for improved understanding of when to implement interventions, uncertainty with respect to optimal duration of treatment, and negative side effects associated with currently approved chemoprevention therapies. None-the-less, the unique biology of the mammary gland, with its postnatal development and conditional terminal differentiation, may permit the resolution of many of these barriers. Specifically, lifecycle-specific windows of breast cancer risk have been identified that may be amenable to risk-reducing strategies. Here, we argue for prevention research focused on two of these lifecycle windows of risk: postpartum mammary gland involution and peri-menopause. We provide evidence that these windows are highly amenable to targeted, limited duration treatments. Such approaches could result in the prevention of postpartum and postmenopausal breast cancers, correspondingly.

Indexed as

Drug DesignAnimalsAntineoplastic AgentsBreast NeoplasmsCell Transformation, NeoplasticDisease ProgressionFemaleHumansRisk FactorsAntineoplastic AgentsMenopauseMetforminNSAIDPostpartum involutionStromal epithelial interactionsTamoxifen

Identifiers

PMID23664839
PMCPMC3980135
OpenAlexW2106549549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.